Objective: Post-cardiac-arrest therapeutic hypothermia improves outcomes in comatose cardiac arrest survivors. This study tests the hypothesis that the efficacy of post-cardiac-arrest therapeutic hypothermia is dependent on the onset and duration of therapy.
M ild therapeutic hypothermia (TH) is the first and only therapy clinically demonstrated to improve survival and neurologic outcome in pa-tients who achieve return of spontaneous circulation (ROSC) after cardiac arrest. Two prospective randomized clinical trials have demonstrated improved outcome of comatose survivors of witnessed outof-hospital ventricular fibrillation cardiac arrest who were treated with prolonged, mild TH (1, 2) . In the study by Bernard et al (1) , the target temperature (33°C) was achieved within 2 hrs after ROSC and maintained for 12 hrs. In the study by the Hypothermia after Cardiac Arrest Study Group (2), the median time to achieve the target temperature (32°C to 34°C) was 8 hrs (the interquartile range was 4 -16 hrs), and hypothermia was maintained for 24 hrs. Improved functional outcome was demonstrated in both studies and survival in the latter. On the basis of these and subsequent studies, the American Heart Association currently recommends TH for comatose survivors of out-of-hospital cardiac arrest when the initial rhythm is ventricular fibrillation, and consideration of TH in patients with other presenting rhythms or after in-hospital cardiac arrest (3) . Although there is growing adoption of post-cardiacarrest TH, the substantial differences in time to achieve the target temperature and duration of therapy in the two major clinical trials have left clinicians guessing as to how this therapeutic strategy should be optimally implemented. In addition, exclusion of non-ventricular-fibrillation rhythms in these studies has left uncertainty as to whether TH is beneficial if the presenting rhythm is pulseless electrical activity or asystole.
Animal studies have thus far failed to systematically optimize TH after cardiac arrest. Published studies have used small numbers of animals with varied models, temperatures, and onsets and durations of therapy. Importantly, when postcardiac-arrest TH is maintained for Յ1 hr, the beneficial effect is lost if the onset is delayed by Ͼ10 -20 mins (4 -6) . These studies support the concept that TH should be initiated as soon as possible after ROSC. However, this concept is challenged by subsequent work in which TH was maintained for Ն24 hrs after cardiac arrest. For example, Hicks et al (7) demonstrated equivalent improvement of outcomes when TH sustained for 24 hrs was initiated either immediately or 1 hr after ROSC following asphyxial cardiac arrest in rats. To the best of our knowledge, there have been no animal cardiac arrest studies that have directly compared different hypothermia onset times beyond 1 hr after ROSC or compared different durations of TH. However, in rodent models of transient forebrain ischemia, both the onset time and duration of TH have an impact on neuroprotection (8 -12) .
The overall goal of this study was to determine whether the benefit of prolonged post-cardiac-arrest TH was dependent on the onset and duration of therapy. To this end we compared TH initiated 0, 1, 4, or 8 hrs after ROSC and maintained for 24 or 48 hrs in a rat model of pulseless electrical activity/asystole cardiac arrest. Outcomes included 7-day survival, 7-day survival with good neurologic function, and survival of selectively vulnerable hippocampal cornu ammonis 1 (CA1) sector pyramidal neurons.
MATERIALS AND METHODS
Cardiac Arrest Model. This study was approved by the University of Pennsylvania Institutional Animal Care and Use Committee (Philadelphia, PA). Male Long Evans rats (Harlan Laboratories, Indianapolis, IN) weighing 325-375 g (approximately 12-14 wks old) were anesthetized with 4% isoflurane, 66% nitrous oxide, and 33% oxygen, orotracheally intubated, and mechanically ventilated using a pressure-controlled ventilator (Kent Scientific, Torrington, CT). Ventilation was titrated to achieve partial pressure end-tidal carbon dioxide of 40 mm Hg (rate ϳ40 breaths/min; peak inspiration pressure ϳ17 cm H 2 O; tidal volume ϳ9 mL/kg) with a positive endexpiratory pressure of 5 cm H 2 O. Anesthesia was maintained with 2% isoflurane, and inspired gas was 66% nitrous oxide and 33% oxygen. Intraperitoneal ampicillin (50 mg/kg) was administered before initial incision. The left femoral vein and artery were cannulated (PE-50 tubing; Harvard Apparatus, Holliston, MA) for arterial and central venous pressure monitoring and intravenous administration of drugs and fluids. Temperature was initially monitored with a needle thermocouple probe placed between the temporalis muscle and skull. Before cardiac arrest, temperature was maintained between 37.0°C and 37.5°C. Electrocardiogram monitoring was performed with electrocardiographic limb leads. Oxygenation was continuously monitored by pulse oximetry (Nonin Medical, Plymouth, MN). Hemodynamic, respiratory, and temperature data were continuously recorded (Chart5 for Windows, ADInstruments, Colorado Springs, CO).
Cardiac arrest was induced by asphyxia as previously described with minor modifications (13, 14) . Rats were chemically paralyzed using intravenous vecuronium (2 mg/kg), isoflurane was discontinued, and inspired gas changed to room air. Asphyxia was induced by disconnecting the ventilator for 10 mins. Circulatory arrest was confirmed by cessation of arterial pulse pressure and reduction of the mean arterial pressure to Ͻ20 mm Hg. Typically, circulatory arrest occurred within 3-4 mins. After 10 mins of asphyxia, mechanical ventilation was reinitiated with no positive end-expiratory pressure using 100% inspired oxygen at a respiratory rate of 40 breaths/min. Intravenous epinephrine (0.005 mg/kg) and bicarbonate (1.0 mEq/kg) were administered and external chest compressions performed at a rate of 350 -400 compressions/min. Rats without ROSC within 2 mins received continued cardiopulmonary resuscitation and up to two additional doses of epinephrine (0.01 mg/ kg). Rats without ROSC after 4 mins of cardiopulmonary resuscitation were considered out of protocol. Following ROSC, inspired oxygen was titrated to maintain a pulse oximetry reading of 94% to 98%. A total of 20 mL/kg 0.9% saline was infused intravenously during the first hour after ROSC. Sixty minutes after ROSC, a telemetric thermoprobe was placed into the peritoneal cavity for subsequent temperature regulation, and the vascular cannulas were removed. Rats were then weaned from mechanical ventilation, extubated, and transferred to a specialized temperature regulation cubicle. Supplemental oxygen was provided for the first 6 hrs after extubation as needed to maintain a pulse oximetry reading above 94%.
Study Protocol. Rats that achieved ROSC after a 10-min asphyxial cardiac arrest were block randomized to normothermia (37°C Ϯ 1°C, n ϭ 42) or TH (33°C Ϯ 1°C) initiated 0, 1, 4, or 8 hrs after ROSC and maintained for 24 or 48 hrs (eight groups, n ϭ 21 per group). Sham injured rats underwent surgical instrumentation under general anesthesia without asphyxiation or cardiopulmonary resuscitation (n ϭ 6).
Induction of TH in 0-and 1-hr onset groups was achieved with an electric fan (Holmes HFH111T-U; Jarden Consumer Solutions, Boca Raton, FL), hand-held spray bottle, and thermopad during mechanical ventilation. After extubation, rats were transferred to the temperature regulation cubicles where the core body temperature was monitored via a telemetric intraperitoneal thermoprobe and regulated using a computerized feedback system that controls a fan, mister, and heating lamp (175 W) as originally described by Colbourne et al (15) . For the TH 4-and 8-hr onset groups, normothermia was actively maintained until the time of TH initiation, and TH was induced in the temperature regulation cubicles. The target temperature was achieved within 30 mins of initiating cooling, and the rats were rewarmed at a rate of 0.5°C/hr. Subcutaneous fluid (5% dextrose in 0.45% saline) and orogastric feeding (20% PMI Micro-Stabilized Rodent Liquid Diet LD101; LabDiet, Richmond, IN) were given twice daily.
The neurologic function score was measured daily. The neurologic function score (Table 1) is based on our previously described neurologic deficit score that has been modified to measure function (500 best to 0 worst) rather than deficit (500 worst to 0 best) (13, 14) . Good neurologic function (GNF) was defined as a neurologic function score of Ն450 out of 500. Primary outcomes were 7-day survival and 7-day survival with GNF. Histology. At 7 days post-cardiac arrest, surviving rats were euthanized by transcardial perfusion fixation (phosphate-buffered saline flush followed by 4% paraformaldehyde) under general anesthesia. Brains were then postfixed in 4% paraformaldehyde at 4°C overnight, cryoprotected in serial 10%, 20%, and 30% sucrose solutions in 0.1 M phosphate buffer, and snap-frozen in chilled isopentane. Coronal sections (50 m thick) were generated using a freezing sliding microtome (Microtome HM 440E; Microm International, GmbH, Walldorf, Germany). Beginning at the rostral end of the hippocampus, every tenth brain section was selected with randomization of the first section for immunolabeling and stereological quantification of CA1 pyramidal neurons. Sections were immunolabeled with primary antibody targeting the neuron-specific marker protein NeuN (MAB 377, Millipore, Billerica, MA; 1:1000) and a goat anti-mouse secondary antibody (Alexa Fluor 488; Molecular Probes, Invitrogen, Eugene, OR; 1:500). Sections were counterstained with Hoechst 33,342 (5.0 g/ mL; Sigma, St. Louis, MO) and mounted with Fluoromount medium (Electron Microscopy Sciences, Hatfield, PA).
Quantification of CA1 pyramidal neurons was performed using fluorescence microscopy and stereologic techniques (Nikon Microphot SA, Nikon Instruments, Melville, NY). The section thickness was measured at high (ϫ200) magnification. Ten percent of the thickness was defined as the guard (buffer) zone above and below the counting region. Ten percent of the area of the outlined CA1 pyramidal layer was selected in an unbiased manner by the stereology software to perform neuronal counting. Only pyramidal neuron nuclei with normal morphology were counted using ϫ200 magnification with a 20 m ϫ 20 m counting frame. The total number of CA1 pyramidal neurons was calculated using the formula n ϭ Α(Qϫ t/h ϫ 1/asf ϫ 1/ssf), where Q Ϫ is the number of cells actually counted, h is the height of the dissector, tsf is the thickness sampling fraction (height of the dissector/section thickness), asf is the area sampling fraction (area of the counting frame/area associated with each step of the stepping motor), and ssf is the section sampling fraction (1/10). Sections adjacent to those used for stereology were selected for standard hematoxylin and eosin staining to confirm the presence of ischemic neuronal pathology.
Data Analysis. Prearrest, intra-arrest, and postarrest hemodynamic and ventilatory vari-ables were compared using one-way analysis of variance with Scheffe post hoc analysis for intergoup comparison. A log rank test was used for between group comparisons of survival time. Pearson's chi-square test was used for between group comparisons of 7-day survival with GNF, and Fisher's exact test was used for contingency tables with expected cell values of Ͻ10. An analysis of variance was used for group comparisons of postischemic neurodegeneration, indexed by the percentages of hippocampal CA1 pyramidal neuron counts compared to normal rats. The percentages were arcsine transformed to normalize the data. It should be noted the postischemic neurodegeneration was conditioned on subject survival at day 7. Mean percentages were reported with their SD. Survival times were presented by Kaplan-Meier curves. p values of Ͻ.05 were considered significant.
RESULTS
Out of a total of 268 rats subjected to cardiac arrest, ROSC was achieved in 222 (83%). Block randomization after ROSC resulted in 21 rats in each of the eight TH treatment groups and 42 rats in the normothermia group. Twelve rats that achieved ROSC were out of protocol after randomization due to malfunction of the temperature regulation system. When this occurred, the rat was excluded from analysis and an additional subject with the same treatment variables was added to the randomization block. Prearrest, intra-arrest, and postarrest hemodynamic and ventilatory variables did not differ between treatment groups ( Table 2) . Temperature curves for each treatment group are presented in Figure 1 . The interaction between onset and duration was not significant for any outcome variable. Therefore, only main effects are reported. Impact of Post-Cardiac-Arrest TH on Survival. The 7-day survival rate was 17% in the normothermia group and 33% for all TH groups combined (log rank test, p Ͻ .001) ( Fig. 2A ). There was no statistical difference in 7-day survival between rats treated with TH for 24 hrs and those treated with TH for 48 hrs (36% vs. 30%, log rank test, p ϭ .65) (Fig. 2B ). Hypothermia initiated 0, 1, 4, and 8 hrs after ROSC resulted in 7-day survival rates of 45%, 36%, 36%, and 14%, respectively (Fig. 2C) . Only TH initiated 0, 1, and 4 hrs after ROSC resulted in a statistically significant improvement in survival (log rank test, p Ͻ .01 vs. normothermia). The 7-day survival was not statistically different among the TH 0-, 1-, and 4-hr groups.
Impact of Post-Cardiac-Arrest TH on Neurologic Outcome. To examine the effect of post-cardiac-arrest TH on neurologic outcome, we compared the percentage of rats that survived with GNF between treatment groups. Survival with GNF was defined as a neurologic function score of Ն450 on day 7 after cardiac arrest. The rate of survival with GNF was higher in rats treated with post-cardiac-arrest TH compared to those maintained at normothermia (17% vs. 2%, p Ͻ .05, Fisher's exact test) (Fig. 3A) . There was no statistical difference in survival with GNF between rats treated with TH for 24 hrs and those treated with TH for 48 hrs (17% vs. 17%) ( Fig. 3B ). Hypothermia initiated 0, 1, 4, and 8 hrs after ROSC resulted in 24%, 24%, 19%, and 0% survival with GNF, respectively ( Fig. 3C ). Only TH initiated 0, 1, and 4 hrs after ROSC resulted in a statistically significant improvement in survival with GNF (Fisher's exact test, p Ͻ .05 vs. normothermia). The 7-day survival with GNF was not statistically different between the TH 0-, 1-, and 4-hr onset groups.
Impact of Post-Cardiac-Arrest TH on Neurodegeneration. To examine the effect of TH on post-cardiac-arrest neuro-degeneration, we compared the number of hippocampal sector CA1 pyramidal neurons surviving 7 days after ROSC between treatment groups. Stereologically quantified hippocampal CA1 sector pyramidal neuron counts are reported as a percentage of counts obtained from sham injured rats. CA1 pyramidal neuron counts were 9% Ϯ 8% of normal in brains from normothermic rats and 53% Ϯ 23% of normal in brains from rats treated with TH (one-way analysis of variance, p Ͻ .0001) ( Fig. 4A ). CA1 pyramidal neuron counts were greater in rats treated with 48-hr TH compared to 24-hr TH (68% Ϯ 15% vs. 42% Ϯ 22%, oneway analysis of variance, p Ͻ .0001) (Fig.  4B ). However, there was no statistical difference in CA1 pyramidal neuron counts based on time of hypothermia onset (0 hrs, 53% Ϯ 27%; 1 hr, 53% Ϯ 19%; 4 hrs, 51% Ϯ 24%; 8 hrs, 65% Ϯ 16%, two-way analysis of variance, p ϭ .5) ( Fig. 4C) . Images from representative brain sections stained with NeuN/Hoechst and hematoxylin and eosin are presented in Figure 5 .
DISCUSSION
This study systematically examined how the beneficial effects of post-cardiac- arrest TH are impacted by the onset time and duration of therapy. Most importantly, our results suggest that the impacts of TH on survival with GNF are comparable when TH is initiated between 0 and 4 hrs after ROSC, but the impact is completely lost when TH is initiated 8 hrs after ROSC. Although the duration of TH had no detectable impact on survival or survival with GNF, we did observe significantly greater protection of hippocampal CA1 pyramidal neurons when TH was maintained for 48 hrs compared to 24 hrs. The potential mechanisms and implications of this differential effect are discussed below.
Optimal Timing for Initiation of Post-Cardiac-Arrest TH. Our results question the concept that TH should be initiated as soon as possible after ROSC. If postcardiac-arrest TH affords comparable outcome benefits when initiated between 0 and 4 hrs after ROSC in humans, the implications for clinical implementation are significant. However, it should be noted that the target temperature was achieved 30 mins after ROSC in our earliest treatment group. Therefore, this study does not address the potential benefit of achieving the target temperature within Ͻ30 mins of ROSC or during cardiac arrest. In fact, short-duration cooling studies suggest that achieving the target temperature during cardiac arrest or within Ͻ10 -20 mins of ROSC could tap into a therapeutic mechanism that is distinct from and potentially additive to the benefits of prolonged post-cardiacarrest TH (4 -6) .
Our results also suggest that there is a therapeutic window after which the benefit of TH on survival and survival with GNF is lost. Although we found this to occur between 4 and 8 hrs after ROSC in our model, the therapeutic window in humans remains to be determined and is likely to vary on the basis of individual circumstances. Furthermore, among survivors, TH appeared to protect hippocampal CA1 pyramidal neurons even when initiated 8 hrs after ROSC. This observation is consistent with evidence that degeneration of hippocampal CA1 pyramidal neurons is delayed for 24 -48 hrs after global brain ischemia in both rats (16, 17) and humans (18, 19) . These results are also consistent with data from our laboratory demonstrating equivalent neuroprotection when hypothermia (33°C) is initiated 1, 2, 4, or 8 hrs after simulated ischemia in organotypic hippocampal slices and maintained for 24 hrs (20) . Using a gerbil model of transient forebrain ischemia, Colbourne et al (12) reported hippocampal CA1 neuroprotection even when hypothermia was initiated 12 hrs after reperfusion, although the protection was less than when initiated 1 or 6 hrs after reperfusion. There are a number of possible explanations for the apparently broader therapeutic window for the neuroprotective effect of TH compared to the effect on survival and neurologic function. First, we do not expect the mechanisms for improved survival with TH to be solely based on neuroprotection. TH has welldocumented effects on the cardiovascular and immune systems that are likely to contribute to post-cardiac-arrest survival independent of neuroprotection, and these independent mechanisms are likely to have their own therapeutic windows. Additionally, the neurologic function score used in this study assesses sensorimotor function and the level of consciousness but not cognitive function. Loss of hippocampal CA1 pyramidal neurons causes learning and memory deficits that are most reliably measured by behavioral cognitive testing. However, in rodents, these tests rely heavily on intact motor function and would be confounded in this study by the presence of significant motor deficits in surviving animals. Finally, it is important to note that the therapeutic window for protection of other selectively vulnerable neuron populations in other brain regions could be different from that of hippocampal CA1 pyramidal neurons.
Existing clinical data provide limited insight into how the time to target temperature affects outcome in humans. In the two major positive clinical trials, the target temperature was reportedly achieved within 2 hrs (1) or at a median time of 8 hrs (the interquartile range was 4 -16 hrs) (2) after ROSC. The latter study suggests a potentially broader therapeutic window than we observed in our rat model. However, it is important to note that cooling was initiated at a median 105 mins (interquartile range 61-192 mins) after ROSC, the median temperature was Ͻ36°C by 2 hrs after ROSC, and half of the patients did reach the target temperature in Ͻ8 hrs (2) . A recent analysis of data from a prospective clinical registry of 975 post-cardiac-arrest patients treated with TH revealed the median time to achieving the target temperature was 4.3 hrs (interquartile range 3.0 -6.7 hrs), and no association between time to target temperature and outcome was detected (21) . Several clinical studies have reported on the feasibility of early postcardiac-arrest cooling and intra-arrest cooling in the out-of-hospital setting (22) (23) (24) (25) . Among these, the only study powered to detect an outcome benefit compared out-of-hospital and in-hospital initiations of cooling after out-of-hospital cardiac arrest and found that out-ofhospital initiation of cooling did not improve outcomes (25) .
Optimal Duration of Post-Cardiac-Arrest TH. Our data suggest comparable survivals and survivals with GNF when TH is maintained for 24 and 48 hrs after ROSC, and there appears to be no significant interaction between the onset and duration of therapy. However, neuroprotection based on hippocampal CA1 pyramidal neuron counts was significantly greater when TH was maintained for 48 hrs compared to 24 hrs. As stated previously, our neurologic function score does not assess memory and therefore is not expected to detect differences in hippocampal neuron injury. Since degeneration of hippocampal CA1 pyramidal neurons is delayed for 24 -48 hrs after transient global brain ischemia in rodents, it is not unexpected that extending hypothermia beyond 24 hrs provides additional neuroprotection (16, 17) .
Existing clinical data provide limited insight into how the duration of TH affects patient outcome. TH was maintained for either 12 or 24 hrs in the two major prospective randomized clinical trials (1, 2) . Recent analysis of data from a prospective clinical registry of 975 postcardiac-arrest patients reported that TH was maintained for 24 hrs in 93% of patients (21) . Pediatric clinical trials are under way comparing the effectiveness of 48-hr TH vs. normothermia after cardiac arrest (ClinicalTrials.gov, identifiers NCT0087864 and NCT00880087) and (C) Comparison of the sham (100%), normothermia (8.8%), and 0-hr (52.6%), 1-hr (52.6%), 4-hr (50.5%), and 8-hr (65%) post-ROSC TH onset groups indicates that TH initiated between 0 and 8 hrs after ROSC results in equivalent neuroprotection among 7-day survivors (two-way ANOVA, p ϭ .5058). Two-way ANOVA was adopted because the hypothermia duration was significant. Normo, normothermia. comparing 24-hr vs. 72-hr TH after cardiac arrest (ClinicalTrials.gov, identifier NCT00797680). Clearly, more clinical studies are needed to discern the optimal duration of post-cardiac-arrest TH.
Study Limitations. While the results presented here provide important and clinically relevant insights into the optimization of post-cardiac-arrest TH, this study has a number of limitations. Most importantly, we were not able to evaluate cognitive function as an outcome variable. This was not attempted because surviving rats in this model have motor deficits of variable severity, which confound interpretation of behavioral studies used to assess cognitive function. Another limitation is that we studied a single duration of cardiac arrest caused by asphyxia resulting in pulseless electrical activity/ asystole. It is possible that the optimal timing and duration of TH are different for other presenting rhythms (e.g., ventricular fibrillation) or durations of cardiac arrest. Furthermore, we did not determine whether there is a duration of cardiac arrest beyond which TH does not improve outcome. This is a clinically important knowledge gap that should be the subject of additional animal and human studies.
Our cardiac arrest model is without comorbidities such as acute coronary syndrome and acute myocardial infarction that are commonly associated with cardiac arrest in humans. It is possible that the therapeutic window for the survival benefit of TH could be altered with such comorbidities. Species differences in the time course of pathophysiologic mechanisms could also result in different therapeutic windows for rats and humans.
In terms of TH variables, we did not evaluate intra-arrest TH or TH achieved within Ͻ30 mins of ROSC, and we did not evaluate TH for durations longer than 48 hrs. We also did not address the issues of optimal temperature or rewarming rate. All of these variables have the potential to impact the efficacy of postcardiac-arrest TH and should be the subject of additional studies.
This translational study does not address the mechanisms by which TH improves survival, improves neurologic function, and reduces postischemic neurodegeneration. Future studies to systematically elucidate these protective mechanisms are essential to achieve optimal implementation of post-cardiac-arrest TH in the greatest number of patients.
CONCLUSIONS
In this rat model of pulseless electrical activity/asystole cardiac arrest, hypothermia initiated between 0 and 4 hrs of Figure 5 . Hippocampal histology after post-cardiac-arrest therapeutic hypothermia (TH). Representative hippocampal sections from sham injured rats or rats 7 days after 10-min asphyxial cardiac arrest followed by normothermia or TH initiated 1 hr after return of spontaneous circulation and maintained for 24 or 48 hrs. (Top two rows) Sections immunolabeled for NeuN (red) and counterstained with Hoechst (blue). Degeneration of CA1 pyramidal neurons is characterized by loss of NeuN immunolabeling (red) and condensed shrunken nuclei (blue). (Bottom two rows) Sections stained by the hematoxylin and eosin method. Classic ischemic neuronal change in the CA1 pyramidal layer is characterized by shrunken dark-staining pyknotic nuclei (blue) and eosinophilic cytoplasm (pink) seen in the high-power images. Scale bar 500 m for low-power images and 50 m for high-power images. Normo, normothermia.
ROSC and maintained for 24 to 48 hrs resulted in comparable improvement in survival and survival with GNF compared to normothermia. However, histologic evidence of neuroprotection was evident when hypothermia was initiated up to 8 hrs after ROSC and was significantly greater when TH was maintained for 48 hrs compared to 24 hrs. Overall, these results provide important insights into the optimization of post-cardiac-arrest TH and suggest potential differences in the optimal variables when targeting survival vs. neuroprotection.
